EU and US could reach trade deal this weekend - Reuters
Daniel K. Podolsky, a director at Agilent Technologies, Inc. (NYSE:A), recently sold shares in the company, according to a Form 4 filed with the Securities and Exchange Commission. The transaction, dated March 31, 2025, involved the sale of 1,819 shares of common stock at a price of $116.462 per share, totaling approximately $211,844. The sale occurred as the stock trades near its 52-week low, with InvestingPro data showing the company’s shares are currently slightly undervalued. Following this sale, Podolsky retains ownership of 35,736.816 shares in the company. This transaction was filed with the SEC on April 2, 2025. The $33.1 billion market cap company maintains a GOOD financial health score according to InvestingPro, which has identified 12 additional key investment tips for Agilent, including insights on share buybacks and dividend consistency. Access the complete Pro Research Report for comprehensive analysis of what matters most about Agilent’s stock.
In other recent news, Agilent Technologies reported strong financial results for the first quarter of 2025, with earnings per share (EPS) of $1.31, surpassing the forecast of $1.27. The company achieved a revenue of $1.68 billion, slightly exceeding the anticipated $1.67 billion. Stifel analysts maintained their Buy rating on Agilent, with a price target of $151, highlighting the company’s favorable market exposures and growth drivers. Agilent also played a significant role in the FDA approval of Autolus Therapeutics (NASDAQ:AUTL)’ CAR T therapy by providing its xCELLigence Real-Time Cell Analysis technology. Additionally, Agilent’s PD-L1 IHC 28-8 pharmDx kit received EU approval for new diagnostic uses, expanding its applications in cancer treatment.
In corporate governance, Agilent announced the upcoming resignation of board member Heidi Kunz, effective May 21, 2025, with the company emphasizing that her departure is amicable. The company continues to make strides in various sectors, including the approval of new uses for its cancer diagnostic kit in the EU, which aids in treatment decisions for lung cancer and melanoma. Agilent’s ongoing strategic initiatives focus on margin expansion and maintaining a steady growth trajectory, with expectations of continued market recovery. The company remains committed to innovation and strategic partnerships, as demonstrated by its collaboration with Autolus Therapeutics and its contributions to the FDA approval process.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.